Neurosense Therapeutics 公司宣布,其产品 Primec 在长达18个月的研究期间,展现出良好的安全性特征,且未出现新的安全信号。这一结果进一步支持了该疗法的安全性评估。
Neurosense Therapeutics 公司宣布,其产品 Primec 在长达18个月的研究期间,展现出良好的安全性特征,且未出现新的安全信号。这一结果进一步支持了该疗法的安全性评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.